Discover

TEVA
Teva Pharmaceutical Industries Limited
39.41
500 x 39.11
200 x 39.52
bid
ask
-
0.80
1.99%
350 @ 05:29 PM
39.40 -0.01 (0.03%)
Ytd26.27%
1y107.20%
39.10
day range
39.84
18.88
52 week range
42.02
Open39.75Prev Close40.21Low39.10High39.84Mkt Cap45.96B
Vol5.60MAvg Vol5.69MEPS0.59P/E66.80Forward P/E12.76
Beta0.82Short Ratio9.08Inst. Own27.24%DividendN/ADiv YieldN/A
Ex Div Date11-28Earning11-0350-d Avg38.63200-d Avg34.341yr Est47.58
Earning
DateForEstimateReportedSurprisesurprise %
2026-11-032026-090.72N/AN/AN/A
2026-07-292026-060.080.02-0.06-75.00%
2026-04-292026-030.50.530.036.00%
2026-01-282025-120.650.960.3147.69%
2025-11-052025-090.680.780.114.71%
2025-07-302025-060.630.660.034.76%
Upgrade / Downgrade
DateFirmActionFromTo
2026-10-15BarclaysUpgradeOverweightOverweight
2026-10-12JP MorganUpgradeOverweightOverweight
2026-10-01TD CowenUpgradeBuy
2026-09-23OppenheimerUpgradeOutperform
2026-09-09Leerink PartnersUpgradeOutperform
2026-09-04UBSUpgradeBuyBuy
Profile
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, oncology, and other areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE, glatiramer acetate injection to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of tardive dyskinesia, chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder; and ProAir RespiClick inhalation powder. It offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. The company has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. Teva Pharmaceutical Industries Limited was founded in 1901 and is based in Tel Aviv-Yafo, Israel.
Insider Holder
DateNameRelationQuantityDescription
2026-06-04BARER SOL JDirector448.01KConversion of Exercise of derivative security
2026-06-04CRANE ROSEMARY ADirector127.74KConversion of Exercise of derivative security
2026-06-04ELSTEIN AMIRDirector2.12MConversion of Exercise of derivative security
2026-03-03FOX CHRISTINEOfficer75.01KConversion of Exercise of derivative security
2026-06-04FRANCIS RICHARD DChief Executive Officer1.18MConversion of Exercise of derivative security
2026-08-02HUGHES ERIC AOfficer134.88KConversion of Exercise of derivative security
Institution Ownership
Report DateOrganizationPositionValuePercentage
2026-06-29Blackrock Inc.63.89M2.52B5.48%
2026-06-29Harel Insurance Investments & Financial Services Ltd.48.14M1.90B4.13%
2026-06-29Phoenix Financial Ltd.42.93M1.69B3.68%
2026-06-29WCM Investment Management, LLC41.32M1.63B3.55%
2026-06-29Clal Insurance Enterprises Holdings Ltd40.60M1.60B3.48%
2026-06-29Menora Mivtachim Holdings Ltd.39.85M1.57B3.42%
Fund Ownership
Report DateOrganizationPositionValuePercentage
2026-07-30VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund17.08M673.01M1.47%
2026-06-29INVESTMENT MANAGERS SERIES TRUST-WCM Focused International Growth Fund13.25M522.13M1.14%
2026-09-29New Economy Fund12.33M485.65M1.06%
2026-06-29VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund11.34M446.91M0.97%
2026-08-30iShares Trust-iShares Core MSCI EAFE ETF8.75M344.75M0.75%
2026-08-30Fidelity Rutland Square TRT II-Strategic Advisers Fidelity Intl Fd.4.66M183.72M0.40%
Dividend
DividendDate
0.0852017-11-27
0.0852017-08-25
0.342017-06-01
0.342017-02-28
0.342016-12-01
0.342016-08-18
Split
SplitDate
2 : 12004-07-01
2 : 12002-12-06
2 : 12000-02-23
2 : 11993-04-14
1 : 11982-08-16